News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Noven Pharmaceuticals Inc. (NOVN) Completes Phase 3 Clinical Program for Investigational Non-Hormonal Therapy for Menopausal Vasomotor Symptoms


3/21/2012 6:03:13 AM

MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has completed the Phase 3 clinical development program evaluating low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms (VMS) associated with menopause (hot flashes). The Phase 3 clinical program was comprised of two studies involving an aggregate of 1,180 subjects from more than 130 centers across the U.S.

Read at BioSpace.com

Related News

comments powered by Disqus
   
Menopause

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES